Incyte10-Q: Competitor namedJul 28, 2026

Incyte faces patent challenges from generic drug competitors for key products JAKAFI and OPZELURA.

What happened

The company is under direct competitive pressure from generic drug manufacturers challenging patents for its major revenue-generating products. This pressure creates a need for solutions that improve operational efficiency, accelerate new R&D pipelines, and manage complex legal proceedings to protect market share.

Source

SEC EDGARJul 28, 2026

Quarterly report (Form 10-Q)

Incyte 10-Q

Filing excerpt

potential generic drug company competitors have challenged certain patents relating to JAKAFI and OPZELURA.

sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htmRead the full source

Other signals in this filing (8)

CFO changeIncyte appoints Suketu Upadhyay as new Executive Vice President and Chief Financial Officer.CFO changeJul 28, 2026
Joint ventureIncyte forms AI collaboration with Genesis Molecular AI to accelerate drug discovery.Joint ventureJul 28, 2026
AI investmentIncyte partners with Genesis Molecular AI to leverage its generative AI platform for drug discovery.AI investmentJul 28, 2026
Cybersecurity incidentIncyte reports it frequently defends against and responds to data security attacks and incidents.Cybersecurity incidentJul 28, 2026
Digital transformationIncyte is making "substantial capital expenditures" to enhance IT systems for planned growth.Digital transformationJul 28, 2026
Cybersecurity investmentIncyte faces significant financial risk up to 4% of global revenue from data privacy laws like GDPR.Cybersecurity investmentJul 28, 2026
Capex increaseIncyte increasing investment in Artificial Intelligence to maintain competitivenessCapex increaseJul 28, 2026
Litigation materialPatents for key products JAKAFI and OPZELURA challenged by generic competitorsLitigation materialJul 28, 2026

Extracted by Autobound

From the Signal API record

Signal: 10-Q: Competitor named

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end: 06/30
Filed: Jul 28, 2026

More 10-Q signals at other companies

SEC 10-QMillerKnoll, Inc.Jeffrey M. Stutz appointed Interim Chief Executive Officer.SEC 10-QSep 28, 2026
SEC 10-QCID HoldCo, Inc.Disclosed material weaknesses in financial reporting due to insufficient accounting staff and controls.SEC 10-QSep 25, 2026
SEC 10-QScholastic CorporationCore school channels decline with fewer book fairs and lower club participation.SEC 10-QSep 25, 2026

The full record

From the Signal API record

Details

CIK: 879169
Accession number: 0000879169-26-000056
Timeframe: Current quarter
Filing year: 2026
Fiscal year: 0
Why it matters: Competitive intelligence
Signal category: Market

Extraction

Confidence: High
Relevance: 70%
Sentiment: Negative
Detected: Aug 4, 2026
signal_type: sec-10q
signal_subtype: competitorNamed

Use this data

Get every 10-Q signal for Incyte and the companies you sell to, in the tools you already use.

Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”
MCP setup guide
Send it to your own tools
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Signal API
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

linkedin_urlValue in the API
industriesValue in the API
employee_count_lowValue in the API
employee_count_highValue in the API
revenueValue in the API
descriptionValue in the API

Signal

signal_nameValue in the API
associationValue in the API

Start Free1,000 free creditsUse it in Claude via MCP

Show the full JSONThe record on this page and the API request

GET /v1/signals/362a8b8a-011f-456c-a0a6-460f91bcb05d returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.

{
  "signal_id": "362a8b8a-011f-456c-a0a6-460f91bcb05d",
  "signal_type": "sec-10q",
  "signal_subtype": "competitorNamed",
  "detected_at": "2026-08-04T07:07:36.31+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "detail": "The company is under direct competitive pressure from generic drug manufacturers challenging patents for its major revenue-generating products. This pressure creates a need for solutions that improve operational efficiency, accelerate new R&D pipelines, and manage complex legal proceedings to protect market share.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "summary": "Incyte faces patent challenges from generic drug competitors for key products JAKAFI and OPZELURA.",
    "excerpts": "potential generic drug company competitors have challenged certain patents relating to JAKAFI and OPZELURA.",
    "relevance": 0.7,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm",
    "filing_date": "2026-07-28",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Competitive intelligence",
    "signal_category": "market"
  }
}

curl https://signals.autobound.ai/v1/signals/362a8b8a-011f-456c-a0a6-460f91bcb05d \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"incyte.com","limit":20}'

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.